Suven Life share price plunges 19% after Alzheimer molecule disappoints in Phase 2 The triple therapy of Masupirdine (SUVN-502) with Donepezil and Memantine proof of concept phase 2 study missed its pre-specified primary endpoint.
Feedback
SUVEN 
Reputation: 2,133 • Dec 2, 2019 5:32 PM
Vote
Comment
Share